Atea Pharmaceuticals, Inc. (AVIR) AI Stock Analysis

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics. Its lead candidate is AT-527, an oral antiviral evaluated in the Phase III SUNRISE-3 trial for COVID-19. The company is also developing AT-752 in a Phase II trial for dengue fever treatment and prevention, as well as AT-281 for RNA viral infections such as yellow fever and Zika virus. Additionally, Atea's pipeline includes Ruzasvir and a co-formulated fixed dose combination of bemnifosbuvir and ruzasvir for chronic hepatitis C virus infection. Headquartered in Boston, Massachusetts, Atea holds a license agreement with Merck & Co., Inc.

Revenue increased at a two-year compound annual growth rate of 98.8% between FY2020 and FY2022. In FY2020, revenue was $48.6M with a net loss of -$10.9M and an operating margin of -22.7%. Revenue expanded by 622.5% in FY2021 to $351.4M, resulting in net income of $121.2M and an operating margin of 39.4%. In FY2022, revenue fell 45.3% to $192.2M, with net income declining to -$115.9M and an operating margin of -68.0%. For the trailing twelve months ended June 30, 2026, revenue stood at $192.2M with EPS of -$2.09, while quarterly revenue growth rose 295.2% year-over-year and quarterly earnings growth increased 264.1%.

As of June 30, 2026, Atea Pharmaceuticals reported $219.5M in cash and short-term investments against total debt of $424,000, leaving net cash at $219.0M. Shareholders' equity was $204.2M, supported by total assets of $232.3M. The company's liquidity position includes a current ratio of 8.13 and a debt-to-equity ratio of 0.00. In FY2025, the company deployed cash toward $25.5M in share buybacks, contributing to an 8.1% decline in share count over five years. Free cash flow was -$122.9M in FY2022.

Atea Pharmaceuticals has an enterprise value of $204.8M and a market capitalization of $346.5M. Its price-to-sales multiple is 1.6x, compared with the median of 4.1x for its US-listed Healthcare peers. The company trades at a price-to-book ratio of 2.1x and an enterprise value-to-revenue multiple of 59.0x. Over the past year, the stock appreciated 38.5%, outperforming the 16.8% return of the S&P 500. Over five years, the stock has declined 89.0% against an 83.0% gain for the index, and its last close of $4.32 sits 11.7% below its 200-day moving average.

Wall Street analyst coverage includes 2 Strong Buy ratings, 0 Buy ratings, and 1 Hold rating. The mean price target is $9.42, implying 118.0% upside compared to the October 16, 2026 close of $4.32. For the fiscal year ending December 31, 2026, consensus estimates project EPS of -$1.99 on revenue of $0. For the following fiscal year, 2 analysts estimate revenue of $30.0M and EPS of -$1.48. Atea exceeded EPS estimates in 1 of the last 4 quarters, with its next earnings release scheduled for November 11, 2026.

This page is an AI-written research summary of Atea Pharmaceuticals, Inc. (AVIR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AVIR income statement, AVIR balance sheet, AVIR key metrics, AVIR analyst forecast, AVIR chart. See the AVIR stock overview for the latest quote and news.